Refractory Diffuse large B-cell lymphoma
Showing 1 - 25 of >10,000
Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)
Active, not recruiting
- Relapsed or Refractory Diffuse Large B-cell Lymphoma
- BEBT-908 for injection
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023
Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-cell Lymphoma
- RC19D2 cell injection
-
Tianjin, Tianjin, ChinaHematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023
DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Mitoxantrone Hydrochloride Liposome Injection
-
Jinan, Shandong, ChinaAffiliated Cancer Hospital of Shandong First Medical University
May 16, 2023
Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)
Not yet recruiting
- Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
- (no location specified)
Sep 5, 2023
Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)
Recruiting
- Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Glofitamab, Poseltinib, Lenalidomide
-
Seoul, Korea, Republic ofSeoul National University Hospital
Nov 28, 2022
Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,
Recruiting
- Diffuse Large B-cell Lymphoma Recurrent
- Diffuse Large B Cell Lymphoma Refractory
- Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Oct 12, 2023
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +7 more
- (no location specified)
Mar 23, 2023
Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)
Recruiting
- Diffuse Large B Cell Lymphoma
- Zanubrutinib, Polatuzumab vedotin and Rituximab
-
Shanghai, Shanghai, ChinaZhongshan Hospital,Fudan University
Jul 10, 2023
DLBCL Trial (maplirpacept (PF-07901801), Glofitamab, Obinutuzumab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- maplirpacept (PF-07901801)
- +2 more
- (no location specified)
May 30, 2023
DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- High-grade B-cell Lymphoma
- Loncastuximab Tesirine
- (no location specified)
Dec 13, 2022
DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- PF-07901801
- +2 more
-
San Juan, Puerto RicoAuxilio Mutuo Cancer Center
Jan 19, 2023
Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)
Active, not recruiting
- Diffuse Large B Cell Lymphoma
- +2 more
-
Duarte, California
- +2 more
Nov 10, 2022
Diffuse Large B Cell Lymphoma Trial (Pembrolizumab, Rituximab, Ifosfamide)
Recruiting
- Diffuse Large B Cell Lymphoma
- Pembrolizumab
- +4 more
-
Headington, Oxford, United Kingdom
- +1 more
Nov 2, 2022
Chidamide in Recurrent and Refractory Diffuse Large b
Enrolling by invitation
- Diffuse Large B-cell Lymphoma
- Chidamide
- +2 more
-
Suzhou, Jiangsu, ChinaSecond Affiliated Hospital of Soochow University
Jan 9, 2023
Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +11 more
- Biopsy
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 3, 2023
Diffuse Large B-cell Lymphoma Trial in Wuhan (Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Mitoxantrone Hydrochloride Liposome
- +2 more
-
Wuhan, Hubei, ChinaDepartment of Hematology Tongji Hospital, Tongji Medical College
Oct 7, 2022
Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- anti-CD19 CAR NK cells
- (no location specified)
Dec 21, 2022
Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- +8 more
- Biospecimen Collection
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Mar 8, 2023
Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in China (ATG-010 and ATG-008)
Recruiting
- Relapsed/Refractory Diffuse Large B-cell Lymphoma
- ATG-010 and ATG-008
-
Chongqing, Chongqing, China
- +5 more
Sep 2, 2022
Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)
Recruiting
- Diffuse Large B Cell Lymphoma
- +3 more
- Low-Dose Decitabine plus anti-PD-1
-
Beijing, Beijing, ChinaChinaPLAGH
Apr 18, 2023
Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory DLBCL Trial in United States (EZM0414)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
-
Chevy Chase, Maryland
- +10 more
Jan 12, 2023
Diffuse Large B-cell-lymphoma Trial in Saint Louis, Cleveland (Venetoclax, Rituximab, Ifosfamide)
Active, not recruiting
- Diffuse Large B-cell-lymphoma
- Venetoclax
- +4 more
-
Saint Louis, Missouri
- +2 more
Nov 14, 2022
Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)
Not yet recruiting
- Relapsed or Refractory B-cell Lymphoma
-
Shanghai, Shanhai, ChinaRuijin Hospital
Sep 29, 2023
Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)
Recruiting
- Diffuse Large B Cell Lymphoma,DLBCL
- PM 8.4 mg/m2
- PM 11.2 mg/m2
-
Chengdu, Sichuan, ChinaWest China Hospital Sichuan University
Jan 15, 2023
Diffuse Large B-cell Lymphoma Trial in Chapel Hill (Polatuzumab vedotin (PV), Rituximab, Hyaluronidase)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Polatuzumab vedotin (PV)
- +6 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Aug 9, 2022